Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

The role of the ste20-like kinase (SLK) in Her2-driven breast cancers

FY 2020-21

Summary
The HER2-positive breast cancer subtype accounts for approximately 25% of all breast cancer and is generally associated with a poor prognosis. Although the development of targeted therapeutics over the past 20 years has improved the prognosis, resistance to these therapeutics remains a significant concern which is driving a need for novel therapeutics. Our lab has been studying the Ste20-like kinase (SLK) for the past 20 years. We have shown that SLK is activated downstream of HER2 through multiple signaling pathways. Consequently, HER2-positive patients tend to exhibit an upregulation in SLK expression correlated with reduced overall survival. This is believed to be in part by SLK's role in promoting cell migration and proliferation. Surprisingly, previous work in our lab showed that loss of SLK in a mouse model of HER2-positive breast cancer significantly accelerated tumor onset and decreased overall survival. This was attributed to the activation of Sox10, a marker of the triple-negative breast cancer subtype. Our results suggest that SLK deletion causes reprogramming of HER2-positive tumors into triple-negative breast cancer. Interestingly, SLK has been shown to regulate cellular functions in a kinase activity-independent manner. It is possible that the loss of SLK scaffolding in SLK-deficient mice activates a pathway which upregulates Sox10 expression. We will test this by assessing the scaffolding function of SLK in tumor progression and Sox10 gene induction. Using CRISPR/Cas technology we have generated mice expressing kinase-inactive SLK. We will cross these mice with HER2-positive breast cancer model mice to assess tumor formation and progression, as well as characterize endpoint tumors. Results will be compared to both wild type and SLK-deficient mice.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449606
Name
Delisle Samuel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of the ste20-like kinase (SLK) in Her2-driven breast cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer Model; Her2 Breast Cancer; Kaplan-Meier; Kinase-Dead Mutant; Ste20-Like Kinase; Transgenic Mice
Abstract
The HER2-positive breast cancer subtype accounts for approximately 25% of all breast cancer and is generally associated with a poor prognosis. Although the development of targeted therapeutics over the past 20 years has improved the prognosis, resistance to these therapeutics remains a significant concern which is driving a need for novel therapeutics. Our lab has been studying the Ste20-like kinase (SLK) for the past 20 years. We have shown that SLK is activated downstream of HER2 through multiple signaling pathways. Consequently, HER2-positive patients tend to exhibit an upregulation in SLK expression correlated with reduced overall survival. This is believed to be in part by SLK's role in promoting cell migration and proliferation. Surprisingly, previous work in our lab showed that loss of SLK in a mouse model of HER2-positive breast cancer significantly accelerated tumor onset and decreased overall survival. This was attributed to the activation of Sox10, a marker of the triple-negative breast cancer subtype. Our results suggest that SLK deletion causes reprogramming of HER2-positive tumors into triple-negative breast cancer. Interestingly, SLK has been shown to regulate cellular functions in a kinase activity-independent manner. It is possible that the loss of SLK scaffolding in SLK-deficient mice activates a pathway which upregulates Sox10 expression. We will test this by assessing the scaffolding function of SLK in tumor progression and Sox10 gene induction. Using CRISPR/Cas technology we have generated mice expressing kinase-inactive SLK. We will cross these mice with HER2-positive breast cancer model mice to assess tumor formation and progression, as well as characterize endpoint tumors. Results will be compared to both wild type and SLK-deficient mice.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Delisle, Samuel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~